Use of health technology assessment in informing clinical development and market access decisions of new medicines
12
3
Issued Date
2019
Resource Type
Language
eng
Rights
Mahidol University
Rights Holder(s)
Faculty of Pharmacy Mahidol University
Suggested Citation
Usa Chaikledkaew, อุษา ฉายเกล็ดแก้ว (2019). Use of health technology assessment in informing clinical development and market access decisions of new medicines. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/49477
Title
Use of health technology assessment in informing clinical development and market access decisions of new medicines
Author(s)
Other Contributor(s)
Abstract
In Thailand, currently the availability of high-cost health interventions, including
pharmaceuticals and medical technologies has been continuously increasing. This has
frequently led to an increase in public and patient expectations as well as a limited healthcare
resource. Therefore, there is a need for evidence-based approach to assist policy makers to
make decision on resource allocation under healthcare budget constraint. Health technology
assessment (HTA) has been increasingly recognized as one of the most useful tools that can
help inform health technology- or health intervention-related policymaking at individual,
institutional, national, and international levels. The objective of this presentation is to provide
the overview and example of the application of HTA in informing clinical development and
market access decisions of new medicines in Thailand. Since 2008, HTA has been increasingly
used for making decision whether drugs should be included in the National List of Essential
Medicines (NLEM). The NLEM is developed in order to include the medicines that are
necessary for the health needs of the Thai population. The NLEM is designed to be an
“optimum list” and it is intended to be a mechanism that supports and promotes rational use of
medicines for all stakeholders, and it is also being a reference for pharmaceutical benefit
scheme for all major health insurance schemes. HTA information has been also considered by
the Pharmaceutical and Therapeutic Committees in hospitals in order to make decision whether
new medicines should be included in hospital formulary list. In addition, it has been recently
applied for price negotiation, development of clinical practice guidelines, and communication
with health professionals.
Description
The 1st Pharmaceutical Sciences Asia Conference 2019 Theme : Pharmaceutical Sciences toward Health Innovation in the Disruptive Era. Bangkok Midtown Hotel, Thailand. August 22, 2019, page 16-17